Oral semaglutide for the treatment of type 2 diabetes

Dec 1, 2018Expert opinion on pharmacotherapy

Oral semaglutide for treating type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Oral semaglutide has shown superiority in reducing glycosylated hemoglobin and body weight compared to placebo and active comparators.

GLP-1 receptor agonists are effective antihyperglycemic drugs that generally do not cause low blood sugar and aid in weight loss.
Oral semaglutide is currently in phase-3 clinical development and represents an advancement in oral peptide delivery.
The safety and tolerability of oral semaglutide are comparable to those of injectable GLP-1 receptor agonists.
Delayed gastric emptying and changes in stomach acidity from oral semaglutide do not appear to significantly affect the absorption of other oral medications.
Further studies are needed to evaluate the effectiveness and safety of oral semaglutide for cardiovascular conditions.

AI simplified

Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body weight reduction. Currently, all approved members of the class require administration by injection. Areas covered: This manuscript reviews oral semaglutide-an experimental GLP-1 receptor agonist in phase-3 clinical development. Available pharmacological and clinical data of the drug are reviewed, and important end-points described. Expert opinion: Oral peptide delivery has become possible with the discovery of absorption enhancers. The clinical development program of once-daily oral semaglutide has shown superiority in reducing glycosylated hemoglobin and body weight in comparison with placebo and active comparators (sitagliptin, liraglutide, and empagliflozin). Safety and tolerability of oral semaglutide is in line with injectable members of the class. Delayed gastric emptying, local increase in pH, and enhanced absorption do not seem to affect the exposure of a number of other oral drugs that have been tested (metformin, digoxin, oral contraceptive ethinylestradiol/levonorgestrel, lisinopril, warfarin, furosemide and rosuvastatin). Clinical questions for further investigation include the effectiveness and safety of oral semaglutide in cardiovascular indications.

Full Text

Full text is available at the source.

View full text ↗

Oral semaglutide for the treatment of type 2 diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief